Pliant Therapeutics, Inc. Price Today
Pliant Therapeutics, Inc.
PLRX
Healthcare
$886.72M
💰
Market Cap
0
💸
Price to Earnings
$-2.8
🎉
EPS
+0
🌳
ESG
Consensus Recommendations
Buy Consensus
Buy |
12 |
Strong Buy |
7 |
Hold |
1 |
Sell |
0 |
Strong Sell |
0 |
PLRX Price Forecast Target
14.7 👉 54.0 +267%
PLRX EPS Forecast
-2.8 👉 -3.5 +26%
Financials
Profit Margin
0 %
Revenue Growth
-100.0 %
Dividend
$ 0
Held Percent
6.6% - Insiders
110.8% - Institutions
-17.4% - Public
Major Fund Holders
-
💰 Deep Track Capital, Lp $84.6M
-
💰 Blackrock Inc. $70.7M
-
💰 FMR, LLC $58.3M
-
💰 Price (T.Rowe) Associates Inc $55.7M
-
💰 First Light Asset Management, LLC $52.9M
Stock Ideas
David Einhorn Portfolio
David Einhorn is one of the most successful long/short equity hedge fund managers of the past decade. As of July 2013, David Einhorn’s Greenlight Capital has returned 19.5% since its inception in 1996. Greenlight Capital’s market beta is around 0.5,…
Jim Chanos Portfolio
Jim Chanos is a revered figure in the world of portfolio management, known for his expertise in short selling and his pivotal role in uncovering fraud at Enron and WorldCom. Hailing from Milwaukee and a graduate of Yale with an economics degree, Ch…
Seth Klarman Portfolio
Seth Klarman's investment prowess is exemplified by his exceptional track record. Since the inception of his fund until 2008, he achieved an impressive compound return-on-investment of 20%. This remarkable achievement showcases his astute investment…
Chase Coleman Portfolio
Chase Coleman, the young and accomplished founder of Tiger Global, has made a significant impact in the investment world. With initial funding from Julian Robertson, Coleman's Tiger Global Management delivered impressive returns, including a remarka…📮FAQ
Some Frequently Asked Questions.
The Pliant Therapeutics, Inc. industry is Biotechnology
The Pliant Therapeutics, Inc. sector is Healthcare
The Pliant Therapeutics, Inc. forecasted predicted Price to Earnings PE ratio is -4.2
The Pliant Therapeutics, Inc. Price to Earnings PE ratio is 0
The Market Capitalization of Pliant Therapeutics, Inc. is $886.72M
There are total of 47094988 float shares with 110.8% held by Institutions and 6.6% held by insiders
The MPliant Therapeutics, Inc. forecasted Earnings per Share EPS is $-3.5
The Pliant Therapeutics, Inc. Earnings per Share EPS is -2.8
The Pliant Therapeutics, Inc. company has $0 gross profits with 0 profit margins
The Pliant Therapeutics, Inc. Earnings Growth is 0% with 0% quarterly earnings growth
The Pliant Therapeutics, Inc. Revenue is $1580000 with -1.0 revenue growth
The price target for Pliant Therapeutics, Inc. stock is $54.0 for the high target and $24.0 for the low target
The consensus analyst recommendations for Pliant Therapeutics, Inc. is Buy, however the decision to buy or sell the stock should be entirely yours, as you are earning your own money and hence responsible on how to allocate and spend them.
The consensus analyst recommendations for Pliant Therapeutics, Inc. is Buy, with the following breakdown:
- Buy: 12
- Strong Buy: 7
- Hold: 1
- Sell: 0
- Strong Sell: 0
The Beta of Pliant Therapeutics, Inc. is 1.1
The dividend of Pliant Therapeutics, Inc. is $0
The dividend yield of Pliant Therapeutics, Inc. is 0%
The biggest institutional and mutual fund holders of Pliant Therapeutics, Inc. stock are
- Deep Track Capital, Lp
- Blackrock Inc.
- FMR, LLC
- Price (T.Rowe) Associates Inc
The Pliant Therapeutics, Inc. ESG Score is 0, with the following breakdown:
- E: 0
- S: 0
- G: 0